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Abstract
 
CD8
 
 
 
 class I–restricted cytotoxic T lymphocytes (CTLs) usually incompletely suppress HIV-1
in vivo, and while analogous partial suppression induces antiretroviral drug-resistance muta-
tions, epitope escape mutations are inconsistently observed. However, escape mutation de-
pends on the net balance of selective pressure and mutational fitness costs, which are poorly
understood and difficult to study in vivo. Here we used a controlled in vitro system to evaluate
the ability of HIV-1 to escape from CTL clones, finding that virus replicating under selective
pressure rapidly can develop phenotypic resistance associated with genotypic changes. Escape
varied between clones recognizing the same Gag epitope or different Gag and RT epitopes, in-
dicating the influence of the T cell receptor on pressure and fitness costs. Gag and RT escape
mutations were monoclonal intra-epitope substitutions, indicating limitation by fitness con-
straints in structural proteins. In contrast, escape from Nef-specific CTL was more rapid and
consistent, marked by a polyclonal mixture of epitope point mutations and upstream frame-
shifts. We conclude that incomplete viral suppression by CTL can result in rapid emergence of
immune escape, but the likelihood is strongly determined by factors influencing the fitness
costs of the particular epitope targeted and the ability of responding CTL to recognize specific
epitope variants.
Key words: cellular immunity • T cell receptor • antigenic variation • T cell receptor speciﬁcity
 
Introduction
 
Cellular immunity is believed to have an important role in
the pathogenesis of HIV-1 infection. Several clinical corre-
lations strongly suggest that CD8
 
 
 
, MHC class I–restricted
CTLs specific for HIV-1 contribute to the control of dis-
ease: temporal correlation of CTL induction to the drop in
peak viremia in acute infection (1, 2), inverse correlations
of CTL activity with clinical progression (3, 4) and viral
load (5) in chronic infection, and the finding of antiviral
CTL activity in some exposed yet uninfected individuals
(6–8). Data from in vitro studies further indicate that CTL
are capable of exerting potent antiviral effects (9–11).
Despite often vigorous CTL responses against HIV-1,
however, most infected persons fail to contain and clear the
infection. Many mechanisms for CTL failure have been
proposed (for reviews, see references 12–17), and a leading
hypothesis is escape through epitope mutation. In evalua-
tions of viral sequences in infected persons, evolving
epitope mutations have clearly suggested escape in a few
longitudinal studies (18–23). Data in acute SIV (24, 25) and
HIV-1 (1, 22) infection have more clearly demonstrated
the emergence of viral CTL escape mutations, suggesting
that CTL of specificities in early versus late infection (26)
may differ in their propensity for escape mutations. Never-
theless, the issue of whether CTL exert immune pressure
leading to viral escape has remained controversial, with
other studies failing to find any evidence for epitope escape
mutation in HIV-1 (27–32). Based on the assumption that
immune pressure and escape mutation are directly corre-
lated, several of these studies have concluded that CTL do
not exert antiviral pressure in vivo.
The emergence of HIV-1 escape mutation depends
upon the net balance between multiple factors that are
poorly understood in vivo. Selective pressure exerted by
the CTL may be influenced by numerous determinants, in-
cluding CTL frequency, epitope specificity, T cell receptor
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properties, and functional state of the CTL. In turn, viral
constraints on the generation of epitope mutations include
the viral fitness cost of the mutations, through either direct
loss of replicative capacity or interference with functions
important for viral persistence. Indirect factors such as ac-
cess of CTL to infected cells, the level of viral replication
and diversity, the types of cells infected, the interplay be-
tween CTL of multiple specificities, and viral immune-
modulatory strategies (such as MHC down-regulation)
likely play a role as well. For an epitope mutation to pre-
dominate in vivo the sum of these factors must favor over-
all fitness of the viral mutant.
It is unclear to what extent the lack of the escape ob-
served for some CTL responses in vivo reflects lack of CTL
pressure or the influence of other factors. Absence of escape
mutations could reflect the selective persistence of CTL
that recognize highly constrained epitopes where change is
not tolerated, inadequate CTL function and immune pres-
sure, or a combination of these and/or other factors.
Therefore, we have evaluated the ability of CTL to induce
escape mutations in HIV-1 in vitro where conditions can
be readily standardized. We used a panel of HIV-1–specific
CTL clones characterized for epitope specificity and HLA
restriction, cocultured with acutely infected HIV-1–per-
missive T cell lines, to evaluate the evolution of escape mu-
tations while controlling for factors that cannot be manipu-
lated feasibly in vivo.
 
Materials and Methods
 
HIV-1–permissive Cell Lines.
 
T1 (33), T2 (34), and H9 (35)
cells were maintained as described previously (10). T1 cells ex-
pressed HLA A2 and B60 as determined by serological typing and
were therefore HLA matched at the restricting class I allele with
all the CTL clones in this study. T2 cells (class I antigen transport-
deficient) or H9 cells (not expressing HLA A2 or B60), being un-
able to present antigen to the CTL studied, served as negative
control cells for all the selection experiments described below.
 
HIV-1 Molecular Clone Point Mutants.
 
NL4–3 (36) Gag p17
point mutations were produced by PCR-based point mutagenesis
(37) of the p83–2 plasmid (38) with sequence confirmation.
These mutants are indicated in Table I.
 
Virus Stocks.
 
HIV-1 IIIB was produced by serial passaging in
H9 cells. NL4–3 and NL4–3 Gag mutant virions were produced
by coelectroporation of H9 cells with p83–2 derivatives and p83–
10 plasmid DNA linearized with EcoR1 (38). NL4–3.1 differed
from wild-type NL4–3 by point mutations in p17 Gag, altering
the NL4–3 sequence from SLYNTIAVL to the consensus
SLYNTVATL sequence (Table I). Low passage virus stocks were
frozen in aliquots at 
 
 
 
80
 
 
 
C until use. Viral titer (TCID
 
50
 
/ml)
was determined by endpoint dilution with C8166 indicator cells
as described previously (39).
 
CTL Clones.
 
HIV-1–specific CTL clones were obtained
from the blood of infected individuals by cloning of PBMC at
limiting dilution, and characterized for specificity and class I re-
striction as described previously (40). Three clones (161JxA14,
18030D23, 115DEC4) recognized the HLA A2–restricted
epitope SLYNTVATL (SL9) in Gag (p17 amino acids [a.a.]
 
*
 
77–85, SL9). One (68A62) recognized the A2-restricted epitope
ILKEPVHGV (IV9) in reverse transcriptase (RT a.a. 309–317).
One (161JD27) recognized the B60-restricted epitope IEIKDT-
KEAL (IL10) in Gag (p17 a.a. 92–101). One (161Jx12) recog-
nized the B60-restricted epitope SEGATPQDL in Gag (p24 a.a.
44–52). Two (STD11, KM3) recognized the B60-restricted
epitope KEKGGLEGL (KL9) in Nef (Nef a.a. 92–100; all posi-
tions are numbered in relation to HXB2 sequences). Of note,
clones 161JxA14, 161JD27, 161Jx12, and STD11 were derived
from a single infected long-term nonprogressing individual, sub-
ject 161J. All CTL were maintained as described previously (10).
 
Passaging of HIV-1 Under Selection by CTL Clones.
 
5 
 
 
 
 10
 
6
 
T1 and control H9 or T2 cells were initially infected with HIV-1
at a multiplicity of 10
 
 
 
1
 
 TCID
 
50
 
/cell for 4 h, followed by two
washes and resuspension in RPMI supplemented with 10% fetal
calf serum and 50 U/ml IL-2 (NIH AIDS Reference and Re-
agent Repository). 5 
 
 
 
 10
 
5
 
 CTL were then added in a total vol-
ume of 10 ml R10–50, followed by culture in a T25 flask in a
humidified incubator with 5% CO
 
2
 
. The cultures were then fed
twice over the next week, followed by harvesting of the cell pel-
let and supernatant virus, which were both saved at 
 
 
 
80
 
 
 
C. The
process was then repeated in a second round of passage using the
supernatant virus, at an initial input of 500 pg p24 antigen (quan-
titated by commercial p24 ELISA kit; Dupont) per 10
 
6
 
 target
cells. The second round was otherwise performed in identical
fashion to the first, with cell pellets and supernatant virus again
saved for subsequent analyses.
 
Analysis of HIV-1 for Susceptibility to Inhibition by CTL.
 
HIV-1
was tested for susceptibility to inhibition using a coculture sys-
tem we developed previously (10). T1 cells (HLA matched at A2
or B60 with all the clones used in this study) were infected with
the passaged supernatant virus at 500 pg p24/10
 
6
 
 cells, washed
twice, and cocultured with CTL at a ratio of 5 
 
 
 
 10
 
5
 
 T1 cells
with 1.25 
 
 
 
 10
 
5
 
 CTL. At two to four day intervals, 1 ml of su-
pernatant was removed for quantitative p24 ELISA (Dupont) and
replaced with fresh medium.
 
Chromium Release Assays.
 
CTL were assessed for specific lysis
of peptide-loaded target cells as described previously (41). Briefly,
target cells were labeled with Na
 
2
51
 
CrO
 
4
 
 (New England Nuclear)
for 1 h with or without synthetic peptide at 100 
 
 
 
g/ml unless
otherwise indicated. Cytolytic activity against these target cells
was then determined by adding effector CTL at a ratio of 5:1
(with appropriate controls for spontaneous and maximal lysis) in a
96-well U-bottom microtiter plate and measuring 
 
51
 
Cr release in
duplicate after 4 h. For determination of the 50% sensitizing dose
of peptides (SD
 
50
 
), the target cells were preincubated with serial
10-fold concentrations of the peptide, and the approximate con-
centration resulting in 50% of maximal killing by the CTL was
extrapolated.
 
Analysis of Passaged Virus for Epitope Mutations.
 
DNA was iso-
lated from the cell pellets after each round of passaging (Puregene
DNA isolation kit; Gentra Systems). Proviral sequences were am-
plified using nested PCR (25 cycles each for two amplifications),
under limiting dilution conditions predetermined by dilution se-
ries to yield approximately one amplification per five reactions.
Positive reactions were then PCR-sequenced using the same
primer set as the secondary amplification.
 
Sequences Around the SLYNTVATL (SL9) and IEIKDTKEAL
(IL10) Epitopes.
 
A sequence spanning potions of Gag p17 and
p24 was amplified using outer primers GCGGAGGCTAGAA-
GGAGAGAG (5LTR768) and TGCTGTCATCATTTCTTC-
TAGTGT (3gag1047), and inner primers ATGGGTGCGAGA-
GCGTCAGTAT (5gag1) and TCTATCCCATTCTGCAGC-
 
*
 
Abbreviation used in this paper:
 
 a.a., amino acid(s).T
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TTC (3gag642). This amplified HIV-1 nucleotides 812–1410
(HXB2 numbering), containing the coding sequences for SL9
(1018–1044) and IL10 (1063–1092).
 
Sequences Around the ILKEPVHGV (IV9) Epitope.
 
A se-
quence spanning a portion of reverse transcriptase was amplified us-
ing outer primers AGAACCTCCATTCCTTTGGA (RT3218F) and
TGGGCCTTATCTATTCCATCTAAAAATAGT (4255R), and
inner primers TACAGCCTATAGTGCTGCCAG (RT3271F)
and GTGCTGGTACCCATGCCAGATAGAC (4164R). This
amplified HIV-1 nucleotides 3292–4139, containing the coding
sequences for IV9 (3474–3500).
 
Sequences Around the KEKGGLEGL (KL9) Epitope.
 
A se-
quence spanning almost all of Nef was amplified using outer
primers AGAGCTATTCGCCACATACC (NEF8736) and
TAGTTAGCCAGAGAGCTCCCA (NEF9589R), and inner
primers CTATAAGATGGGTGGCAAGTG (NEF8780F) and
TTATATGCAGCATCTGAGGGC (NEF9495R). This ampli-
fied HIV-1 nucleotides 8810–9498, containing the coding se-
quences for KL9 (9069–9095).
 
Results
 
CTL Clones Recognizing the Same Epitope Exhibit Differen-
tial Tolerance for Epitope Mutation.
 
HIV-1–specific CTL
clones vary in their ability to recognize epitope mutants as
determined by synthetic peptide titrations, as has been
shown for a comprehensive study (31) of CTL recognizing
a common HLA A2–restricted epitope in Gag p17 a.a. 77–
85, SLYNTVATL (SL9). To evaluate whether this poor
recognition of exogenously added peptide variants affects
the antiviral function of CTL, two SL9-specific clones
from different persons were tested for their ability to sup-
press a panel of HIV-1 mutants differing in SL9 sequence
(Fig. 1). Clones 161JxA14 and 18030D23 demonstrated
clear differences in their ability to act upon HIV-1 with
variation in SL9. Whereas 161JxA14 still suppressed virus
with the --F------ variant of SL9, 18030D23 did not.
Conversely, the --F--I--- and -----I-V- variants were sup-
pressed by 18030D23 but not by 161JxA14. Previously
published (31) 50% sensitizing dose peptide concentrations
(SD
 
50
 
) for recognition of exogenously added peptide vari-
ants by 18030D23 indicated that SL9 and variants --F--I---
and -----I-V- were relatively well-recognized (SD
 
50
 
 
 
 50
ng/ml), whereas the other poorly inhibited variants were
inefficiently recognized (SD
 
50 
 
  
 
500 ng/ml). Although
161JxA14 was not evaluated in that study, two other SL9-
specific clones from the same subject exhibited good rec-
ognition of SL9 and the --F------ variant (SD
 
50
 
 
 
 10 ng/
ml) and poor recognition of the other variants (SD
 
50 
 
 
 
 400
ng/ml). Our findings therefore indicated that CTL clones
targeting the same epitope can vary significantly in their
antiviral activity against HIV-1 containing epitope variants,
providing functional confirmation for prior findings using
exogenously added synthetic peptide.
 
HIV-1 Can Rapidly Escape from CTL Pressure through
Epitope Mutation.
 
To examine whether HIV-1 could re-
spond to selective pressure against CTL under controlled
conditions, a molecular clone virus was passaged in the
presence of the SL9-specific CTL clone 161JxA14 under
conditions favoring vigorous viral replication (Fig. 2). The
 
Table I.
 
NL4-3–based SL9 Variant Viruses
 
DNA sequence A.A. sequence
 
TCA TTA TAT AAT ACA GTA GCA ACC CTC SLYNTVATL
 
(Consensus SL9 sequence, NL4-3.1)
 
TCA TTA TAT AAT ACA ATA GCA GTC CTC -----I-V-
 
(Wild-type NL4-3)
 
TCA TTA TTT AAT ACA GTA GCA ACC CTC --F------
TCA TTA TTT AAT ACA ATA GCA ACC CTC --F--I---
TCA TTA TAT AAT CTA GTA GCA GTC CTC ----L--V-
 
The panel of SL9 mutant viruses used in Fig. 1 is indicated. Point mutagenesis was performed on NL4-3 to alter the epitope; changed nucleotides
are underlined. Amino acid sequences of the epitope relative to the consensus SL9 sequence are also indicated.
Figure 1. HIV-1–specific CTL clones differentially inhibit replication
of HIV-1 point mutants. A panel of HIV-1 NL4–3–based viruses con-
taining point mutations in the SL9 epitope was screened for inhibition of
viral replication by the SL9-specific CTL clones 161JxA14 and
18030D23. Viral replication as assessed by quantitative p24 ELISA was
measured 7 d after addition of CTL to acutely infected T1 cells. Inhibi-
tion of each virus by each clone (in log10 units) was determined by com-
paring p24 production in the presence and absence of CTL. Plotted in
this figure are the ratios of suppression of HIV-1 with each SL9 mutation
relative to virus with the index SL9 sequence SLYNTVATL.T
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viruses resulting from this passaging were then screened
for development of resistance to that clone and sequenced
for epitope changes (Fig. 3). Selected virus and negative
control virus (passaged in parallel in cells unable to present
antigen to the clone) were tested for phenotypic sensitivity
to that Gag-specific clone or a control HLA A2–restricted
RT-specific clone (68A62). Virus that had previously un-
dergone one week of selective passaging remained sensi-
tive to the selecting CTL (Fig. 3, bottom left), but virus
that had undergone two weeks of selective passaging de-
veloped resistance (Fig. 3 bottom right, see also Fig. 6), as
indicated by inhibitory activity relative to the control RT-
specific CTL clone. Negative control virus from both pas-
sages remained sensitive (Fig. 3 top row). Limiting dilu-
tion sequencing revealed that the control virus remained
unaltered in the Gag epitope, while CTL-selected virus
was also unaltered after 7 d of culture (Fig. 3 bottom left),
but contained a predominance of a mutation in the
epitope to -----I--- after the second round of passage (Fig.
3, bottom right; see also Fig. 6). Mutation was confined to
the SL9 epitope and not observed in flanking sequences
(Table II,
 
 
 
and unpublished data). This epitope variant was
poorly recognized by 161JxA14 in a peptide titration
chromium release assay, with an SD
 
50
 
 of 
 
 
 
100 
 
 
 
g/ml
(Fig. 4). These data indicated that a specific monoclonal
genetic escape mutation arose within two weeks of selec-
tive pressure by the Gag-specific CTL clone, conferring
phenotypic resistance.
 
Different CTL Clones Recognizing the Same Epitope Vary in
Their Susceptibility to HIV-1 Escape.
 
Given these results,
two other CTL clones recognizing the same Gag SL9
epitope (18030D23 and 115DEC4) derived from two ad-
ditional HIV-1–infected persons were also tested in the
same manner (Fig. 5 and Table II). Resistance was not ob-
served for either Gag-specific clone after two passages
(18030D23 Fig. 5, 115DEC4 unpublished data). Epitope
sequencing revealed a minority epitope mutation only in
virus that had previously undergone two passages under se-
lection by 18030D23 (Fig. 5 and Table II) and none for
115DEC4 (Table II). The -----I--- escape mutation ob-
served for 161JxA14 above therefore did not arise for ei-
ther of these other two clones recognizing the same
epitope. Consistent with the absence of this mutation after
Figure 2. Scheme for passaging HIV-1
under selective pressure by CTL. Defined
starting virus was grown in T1 cells (able to
present antigen to the selecting CTL clone)
or a control cell line (unable to present anti-
gen to the CTL due to HLA mismatching
or antigen transport defect) in the presence
of a selecting CTL clone for 7 d. After this
first passage, proviral DNA and supernatant
HIV-1 were harvested. These were then
used for the analyses of sensitivity to CTL
and epitope sequence (Figs. 3, 5, 6, and 7).
The virus was also further passaged under
the same conditions for a second passage, af-
ter which proviral DNA and supernatant
HIV-1 were again harvested for analysis.
Figure 3. The SL9-specific CTL clone 161JxA14 is rapidly escaped by
HIV-1. HIV-1 IIIB previously passaged (Fig. 2) under selective pressure
in HLA A2-matched T1 cells (bottom row) or no selective pressure in
HLA mismatched H9 cells (top row) by the CTL clone 161JxA14 (recog-
nizing the Gag epitope SL9) for 1 (first column) or 2 (second column) wk
of passage was tested for susceptibility to this clone or the control clone
68A62 (recognizing an RT epitope). Replication of the control and
161JxA14-selected viruses in T1 cells in the absence (open triangles) or
presence (open and closed circles) of CTL is shown. These control and
CTL-selected viruses were also sequenced for the SL9 epitope at limiting
dilution, and the viral sequences are indicated below each graph. Similar
results (decreased susceptibility to inhibition and -----I----- mutation ob-
served after two weeks) were obtained in three experiments using HIV-1
IIIB and one using the molecular clone NL4–3.1 (Table II, Fig. 5, and
unpublished data).T
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selection by 18030D23, this epitope variant was previously
shown to be somewhat cross-recognized by this clone
(with a peptide SD
 
50
 
 of 
 
 
 
100 ng/ml [31]), and the escape
virus from 161JxA14 was also noted to be sensitive to inhi-
bition by 18030D23 (Fig. 6). Of note, all three clones
demonstrated different T cell receptor sequences (unpub-
lished data). Together, these data indicated that different
CTL recognizing the same epitope differ in susceptibility
to viral escape mutation, depending on their individual
ability to recognize specific epitope variants. Thus, proper-
ties specific to the T cell receptor of individual CTL play
an important role in determining the repertoire of epitope
mutations that can contribute to escape by differential
pressure on the possible mutants.
 
HIV-1 Escape from Other Gag- and RT-specific CTL Clones
Also Occurs Variably, and Tends to Be Monoclonal.
 
Evolu-
tion of viral resistance against CTL recognizing other
epitopes in Gag and RT also was evaluated (Table II).
HIV-1 passaged under selective pressure by the HLA A2-
restricted RT-specific clone (68A62) contained a single
epitope point mutation, again only seen after the second
week of passaging, leading to resistance after two weeks of
selection, altering ILKEPVHGV to ----L---- (SD
 
50
 
 of 50
pg/ml versus 
 
 
 
100 
 
 
 
g/ml, unpublished data). Two clones
(161JD27 and 161Jx12) recognizing different HLA B60-
restricted Gag epitopes failed to select for phenotypic resis-
tance, or detected mutations (161JD27 in Table II, not
done for 161Jx12) under these conditions. Thus, for the
Gag- and RT-specific CTL tested in general, epitope es-
cape mutation was observed after 2 wk of passaging if at all,
and consisted of a single virus population differing by a sin-
gle amino acid. Although multiple potential point muta-
tions can ablate recognition for any given CTL clone (14,
31), only one or no escape mutations arose under pressure
by the clones tested here, indicating that the combined fit-
 
Table II.
 
Comparison of HIV-1 Escape from Multiple CTL Clones Recognizing Epitopes in Gag and RT
 
CTL Sequence Frequency
161JxA14 (Gag p17, A2)
 
CRQILGQLQPSLKTGSEELR
 
SLYNTVATL
 
YCVHQRIDVKDTKEALDKIE
--------------------
 
---------
 
--------------------
 
1/10
 
--------------------
 
-----I---
 
--------------------
 
8/10
 
--------------------
 
-----I-V-
 
--------------------
 
1/10
115DEC4 (Gag p17, A2)
 
CRQILGQLQPSLQTGSEERR
 
SLYNTVATL
 
YCVHQRIEIKDTKEALDKIE
--------------------
 
---------
 
--------------------
 
16/16
18030D23 (Gag p17, A2)
 
CRQILGQLQPSLQTGSEELR
 
SLYNTVATL
 
YCVHQRIDVKDTKEALDKIE
--------------------
 
---------
 
--------------------
 
13/15
 
--------------------
 
-------A-
 
--------------------
 
2/15
68A62 (RT, A2)
 
LTEVVPLTEEAELELAENRE
 
ILKEPVHGV
 
YYDPSKDLIAEIQKQGQGQW
------------------------------------------------- 6/12
------------------------L------------------------ 6/12
161JD27 (Gag p17, B60) SEERRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAAD
-------------------------------------------------- 9/10
-----------------------------------K-------------- 1/10
HIV-1 passaged in the presence of CTL (protein specificity, HLA restriction) was sequenced for mutations in and around the recognized epitope.
The index epitope and flanking sequences are given, and changes induced by passaging with the CTL are noted below. The frequency of the changes
after the second passage (14 days) is given. The epitopes are in bold. Other flanking sequence mutations were not observed in regions sequenced (at
least 150 nucleotides upstream and downstream of each epitope). 
Figure 4. The SL9 variant -----I--- is poorly recognized by
161JxA14. Lysis of target cells labeled with serial dilutions of exogenously
added SL9 or -----I--- variant peptides was assessed by standard chro-
mium release assay.T
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ness costs and recognition of most potential escape variants
outweighed the selective pressure exerted by the CTL on
the original epitope. Furthermore, although epitope flank-
ing mutation leading to altered epitope processing has been
proposed as a mechanism of escape (42), such changes were
not observed (Table II). In general, these findings suggested
that escape is limited for CTL recognizing epitopes in
structural proteins, due to the fitness constraints of particu-
lar epitope variants among potential escape mutations.
Nef-specific CTL Rapidly Select Polyclonal Mutations In
Vitro. Previous observations that nonrecognized variants of
the A2-restricted Gag epitope are uncommon in vivo (31)
and that escape occurs readily against Tat- and Nef- but
not Gag-specific CTL in acutely SIV-infected macaques
(24, 25) prompted evaluation of other CTL clones specific
for early expressed proteins. Analysis focused on Nef, a
protein commonly targeted by CTL during acute HIV-1
infection (26). HIV-1 was passaged under selection by two
CTL clones recognizing an epitope in Nef (STD11 and
KM3), again with parallel negative control viruses. Passag-
ing with these CTL produced a strikingly consistent pattern
of rapid escape and polyclonal mutation compared with the
RT-and Gag-specific CTL. Virus exposed to a single
round of selective passage with the clones became highly
resistant (Fig. 7, bottom left), compared with the negative
control virus (Fig. 3, top left). Resistance was associated
with a polyclonal mixture of substitution mutations in the
epitope and upstream frameshift/stop mutations. Almost all
of the frameshifts were due to single adenosine insertions in
a stretch of adenosines at the beginning of the epitope (nt.
positions  1 to  3 relative to the start of the epitope), or
single thymidine deletions in a stretch of thymidines just
before the epitope (nt.  6 to  2). Because the input virus
was a molecular clone (NL4–3.1), these mutations arose de
novo within the seven days of selection (three to seven rep-
licative cycles, given an estimated HIV-1 generation time
of 1 to 2 d [43, 44]). Downstream epitope flanking muta-
tions were not observed, and multiple upstream mutations
disrupted epitope expression. Comparison of the number
of mutations induced by the Gag/RT-specific CTL clones
compared with the Nef-specific CTL clones indicated a
significant difference (P   0.0001). Moreover, a Nef-spe-
cific CTL line recognizing a B*15-restricted epitope in-
duced a similar pattern of polyclonal epitope mutations and
upstream frameshifts (unpublished data). These data there-
fore indicated that the tested Nef-specific CTL more
readily induce escape mutations, including reading frame
disruptions, compared with RT- and Gag-specific CTL in
vitro. This was further evidence of a key role for fitness
constraints in determining escape, given the dispensability
of Nef for viral growth in this culture system (45).
Discussion
In contrast to antiretroviral drugs, which readily induce
escape mutations in their target proteins under conditions
of persistent viremia, escape mutations against CTL re-
sponses have not been consistently observed in vivo. Lack
Figure 5. Another SL9-specific CTL clone 18030D23 does not rapidly
select resistant virus. The experiment depicted in the Figure 3 was re-
peated with another clone 18030D23 (derived from another infected per-
son, also recognizing the SL9 epitope) using HIV-1 NL4–3.1 (see also
Table II). Again, control virus was passaged under no selective pressure
(this time in TAP-deficient T2 cells) or with selective pressure (in HLA
A2–matched T1 cells) by the selecting clone (18030D23). These viruses
were tested for inhibition by 18030D23 or 68A62 as indicated, and SL9
sequences for these tested viruses are again shown. In a repeat experiment
using strain IIIB, neither phenotypic resistance nor SL9 mutation was ob-
served for 18030D23-selected virus (unpublished data).
Figure 6. 18030D23 readily inhibits the escape virus for 161JxA14.
HIV-1 NL4–3.1 viruses previously passaged (Fig. 2) for 2 wk under no
selective pressure in TAP-deficient T2 cells (A) or selective pressure in
HLA A2–matched T1 cells (B) by 161JxA14 were tested for susceptibility
to viral inhibition by clones 161JxA14 and 18030D23. Below each graph
are the SL9 sequences of the tested viruses.T
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of observed escape often has been interpreted to reflect a
lack of antiviral pressure by CTL, given the high mutation
and replication rates of HIV-1 (46) that should ensure tre-
mendous diversity in CTL epitopes (14). The degree of
antiviral pressure by CTL is clearly an important consider-
ation, but escape probably is determined by the relative
balance of selective pressure and fitness costs of potential
escape mutations. One study has demonstrated reversion of
escape mutations after loss of CTL pressure (47), support-
ing this concept. The replicative capacity of any given vir-
ion is determined by its intrinsic fitness and the pressure
applied by the immune system. Thus, for any given
epitope mutation to gain predominance over the initial
epitope within a viral population facing recognition by
CTL, its net balance of recognition by CTL and replicative
fitness must outweigh that of the wild-type. Lack of ob-
served CTL epitope escape mutations in vivo therefore
could be due to any combination of insufficient pressure
on the wild type epitope, good pressure on variants, or
high fitness costs to variants.
These interactions are difficult to evaluate in vivo, where
it is impossible to isolate factors such as CTL specificity and
function, and input viral sequence. To study HIV-1 escape
from CTL in a controlled manner, we devised a strictly
defined in vitro system. Previously, in vitro CTL escape
mutations had been shown for murine lymphocytic
choriomeningitis virus (48) and HIV-1 (11). Thus we
systematically examined a panel of HIV-1–specific CTL
clones for their ability to drive escape mutations in HIV-1
in vitro, under conditions that allowed vigorous viral repli-
cation in the face of weakly inhibitory concentrations of
CTL. This system allowed us to evaluate defined factors
that influence the interaction of CTL with HIV-1.
We first examined three CTL clones specific for the
SL9 epitope in p17 Gag, a common and well-described
epitope that appears to develop escape mutations infre-
quently in vivo (31). These clones exhibited consistently
different susceptibility to escape mutation. One clone
(161JxA14) rapidly selected phenotypically resistant virus
containing a monoclonal mutation (-----I---), after 14 d
of selection. The ability of this variant to arise and pre-
dominate rapidly suggested that this mutation did not
carry a substantial fitness cost, at least in the IIIB and
NL4–3 strains used here in vitro. Two other clones, how-
ever, did not induce the escape mutation selected by the
first. One clone variably selected a different monoclonal
mutation (-------A-), and the other induced no detectable
mutations. We further confirmed that the -----I--- variant
was well recognized by at least one of these two clones,
indicating that it escapes 161JxA14 and not the other
clone. The variability between these clones was consistent
with the finding that their T cell receptors (TCRs) are
distinct in terms of V  usage (unpublished data). These
data indicate that selective pressure on various epitope
mutants is clone-specific, and thus the selective pressure
applied on any given potential escape mutant can mark-
edly differ between clones.
Another interesting aspect of these data was the clonality
of escape when it did occur. Further experiments with
other Gag- and RT-specific CTL revealed the same pat-
tern of monoclonal or no escape. Because CTL nonrecog-
nition should be readily achievable through single point
mutations abrogating TCR binding (as demonstrated for
SL9-specific clones previously [31]), epitope processing, or
MHC-I nonbinding, this narrowness of escape suggested
that the replicative fitness constraints for potential escape
mutations usually outweighed the replicative advantage
gained by nonrecognition by the CTL. For example,
MHC-I presentation of epitopes is highly dependent on in-
dividual anchor amino acids (49) and should be easily dis-
rupted by any of dozens of single point mutations, yet no
such mutations were seen after CTL selection here in vitro
or in extensive studies of SL9 sequences in vivo (31, 50).
These data suggest that fitness costs may play a substantial
role in determining whether escape occurs in SL9 and
other epitopes in structural proteins, and may partially ex-
Figure 7. The Nef-specific CTL clone STD11 very rapidly selects re-
sistant virus that contains multiple mutations. HIV-1 NL4–3.1 previously
passaged (Fig. 2) under selection by STD11 (recognizing the Nef epitope
KEKGGLEGL) was tested for phenotypic sensitivity to STD11 or 68A62,
as well as genetic changes in the Nef epitope recognized by STD11.
Frameshift   frameshift mutations upstream of the epitope. Early stop  
substitution mutation upstream of the epitope leading to a stop codon.
Similar results were obtained in another experiment using STD11 and
HIV-1 IIIB (unpublished data) and two experiments using another clone
KM3 of the same specificity (also with both NL4–3.1 and IIIB). Similar
results (polyclonal epitope mutations and upstream frameshifts) were also
obtained with Nef-specific CTL recognizing an HLA B15-restricted
CTL clone and H9 target cells (unpublished data).T
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plain why SL9 escape mutations are uncommon in vivo
(31). A study of another Gag epitope has suggested more
directly that fitness constraints are an important determi-
nant of escape (47). In sum, these findings strongly suggest
that fitness considerations play a central role in determining
whether escape mutations arise within a CTL-pressured
HIV-1 population, particularly in the setting of a poly-
clonal response to viral epitopes (51).
When Nef-specific CTL were evaluated, escape was
highly polyclonal and arose much more rapidly and com-
pletely. Furthermore, the mutations occurred in multiple
sites of the epitope (TCR binding and HLA-binding an-
chor residues) and were dominated by upstream frame-
shifts resulting in functional deletion of the epitope. At
least two factors likely contributed to the higher degree of
escape we observed with Nef-specific CTL clones. First,
unlike Gag and RT, Nef is entirely dispensable for viral
replication in our culture system (45) and thus changes in
Nef (including functional deletion through frameshifts)
probably occur with no fitness cost to HIV-1 in vitro. Sec-
ond, Nef-specific CTL may exert more immune pressure
than Gag- or RT-specific CTL. This is seen in the mark-
edly more efficient suppression of viral replication by
Nef-specific CTL (Fig. 7), further supported by our obser-
vation that Nef-specific CTL are reproducibly more in-
hibitory for HIV-1 replication than Gag- or RT-specific
CTL in vitro (unpublished data), and recent data that the
earlier epitope expression in Nef allows more efficient
CTL clearance of infected cells (52). Intriguingly, autolo-
gous infusion of exogenously expanded Nef-specific CTL
has been reported to result in epitope deletion in vivo
(19), although generally the nef reading frame is remark-
ably conserved in vivo (53, 54). Because Nef-specific CTL
are common, these findings underscore the functional im-
portance of Nef for HIV-1 pathogenesis, as reflected by
the apparently high fitness costs in vivo (but not in vitro)
favoring its conservation.
Our data may be relevant to several further in vivo ob-
servations concerning CTL specificity. During the course
of HIV-1 infection, specificity appears to evolve from tar-
geting accessory proteins such as Nef initially to targeting
structural proteins in chronic infection (26). Moreover, el-
egant studies in the SIV model have shown that such early
CTL recognizing Tat and Nef induce escape mutations at
far higher rates than those recognizing Gag (24, 25, 55). A
hypothesis consistent with our data and these findings is
that the most antiviral CTL arise early in infection, prefer-
entially targeting early expressed proteins such as Tat and
Nef and being of the highest avidity. However, these CTL
are rapidly escaped by nonrecognized epitope mutations,
leading to loss of antigen to drive persistence of these CTL.
Other less efficient CTL recognizing structural proteins can
then predominate, and those recognizing the most con-
strained epitopes continue to persist into chronic infection.
This hypothesis would explain the observations of shifting
CTL specificities and more consistent findings of escape
mutations against early CTL versus late CTL, although fur-
ther study will be required to support or disprove this sce-
nario. Another aspect concerning the difference between
early and late CTL is the suggestion that the high avidity of
early CTL may be a determinant of immune pressure and
escape (55). However, the Gag SL9-specific clones
161JxA14 and 18030D23 had SD50 measurements of 20
ng/ml versus 1 ng/ml, and the lower avidity clone
161JxA14 appeared to be more prone to escape. Although
the Nef-specific clones were of high avidity (SD50   100
pg/ml) and induced more escape, it is difficult to isolate the
effects of avidity and epitope mutation fitness costs, and
further study will be required to delineate the potential role
of avidity in escape.
Another topic of intense interest has been the issue of
CTL function in vivo. The clones used for this study were
highly selected as potent killers in cytolysis assays. Numer-
ous investigators have suggested that CTL function is di-
minished in vivo, in reports of lacking CD4 T helper re-
sponses (56, 57), diminished CTL production of cytolytic
enzymes (58), lack of effector phenotype (59), loss of im-
portant signaling molecules such as CD3  (60), and im-
paired homing to sites of viral replication (61). Our data
hint that CTL pressure in vivo may be suboptimal. Al-
though clone 161JxA14 rapidly and reproducibly selected
the -----I--- escape mutation in vitro, this mutation ap-
peared to be in the minority or lacking in the person
(Subject 161J) from whom this clone was isolated (1/4
--F--I---, 3/4 --F------; reference 31), consistent with
suboptimal selective pressure in vivo. Although suggestive,
we cannot exclude that this is due to factors other than
suboptimal pressure, such as other CTL exerting pressure
on the -----I--- variant, or differing fitness costs between
the virus in vivo and the IIIB/NL4–3.1 isolates in our
study. Of note, the SL9-specific CTL response in 161J ap-
pears to be nearly monoclonal (unpublished observation).
Clone STD11 recognizing the Nef epitope KEKGGLEGL
also was isolated from 161J, and the predominant epitope
sequence in vivo was -K------- (62), which was a minor
sequence selected by this clone in vitro. Again, this differ-
ence could be due to inadequate selective pressure, differ-
ential pressure on the variants by other CTL, or different
fitness costs. Since Nef is dispensible in vitro, the latter pos-
sibility could be particularly significant.
In conclusion, we find that HIV-1 can readily escape
from some virus-specific CTL, indicating that CTL can ex-
ert selective pressure that exceeds viral fitness costs. Not all
CTL clones are equally susceptible to escape mutations.
The interplay of multiple factors affecting immune pressure
and viral fitness determines the likelihood of viral escape.
Both immune pressure and fitness costs may be influenced
by the particular epitope targeted, the protein targeted, and
the TCR structure of the selecting CTL clone. Study of es-
cape mutations in vitro may permit a focused evaluation of
important issues regarding the role of CTL specificity and
function in the immune control of HIV-1. Such an ap-
proach may be useful in dissecting the determinants of
CTL success and failure in immunopathogenesis and vac-
cine development, where it may be crucial to optimize the
specificity of antiviral responses.T
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